MedTrace Logo

Assessing the Glycaemic Index of Two Different Cultivars of Date Fruit

NCT03769389 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-12-07

No results posted yet for this study

Summary

Fruit of the date palm (P. dactylifera) may be considered as an emerging and potential candidate for the development of health-promoting foods, owing to its high nutritional values.

Furthermore, aqueous extracts of dates have previously been shown to have potent antioxidant activity, because they inhibit in vitro lipid and protein oxidation and possess free radical scavenging capacity.

Although the high sugar content of date fruit has always been a concern, date fruit has been regarded as a low-GI to medium-GI food. However, very limited, inconsistent and contradictory information is available on the glycaemic index values of different date varieties, which may be attributed to both the methodology as well as other food factors. Date consumption is high among people of Arabic origin, where it's very common for them to be eaten with coffee or yoghurt. Therefore, in view of these concerns, the objective of this trial is to evaluate the glycaemic response of two different varieties of dates, named Birhi \& Khassab, in an early maturation stage (Rutab stage), when mixed with 0% fat yogurt, on ten healthy participants aged between 18 and 45.

Conditions

  • GI Glycaemic Index Healthy Volunteers
  • GL Glycaemic Load Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

Birhi

Birhi which contain the following: 43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt

DIETARY_SUPPLEMENT

Khassab

34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt

DIETARY_SUPPLEMENT

placebo

50g of pure glucose dissolved in 100ml of water

Sponsors & Collaborators

  • Newcastle University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-16
Primary Completion
2018-05-31
Completion
2018-06-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03769389 on ClinicalTrials.gov